1. History​

History​

Timeline of Helixmith's growth and
​development of new products.

개인정보처리방침

닫기

이메일무단수집거부

닫기
  • 2020’s
  • 2010’s
  • 2000’s
  • 1990’s
2020
  • 09

    Establishment of Helixmith Subsidiaries - Neuromyon, Cartexell​.

  • 07

    VM202-CMT(Charcot-Marie-Tooth disease treatment) phase 1/2a initiated in Korea.​

  • 06

    VM202-DPN(Diabetic neuropathy treatment)-Second Phase 3 initiated in U.S.​

  • 05

    Experimental animal facility opened​.

  • 04

    President Yoo Seung-shin Appointed as CEO - Kim Sun-young
    & Yoo Seung-shin became Individual Representatives​.

2019
  • 11

    Moved headquarters to new Magok Building, Seoul.

  • 07

    VM202-CLI(Critical Limb Ischemia), initiated phase 3 clinical trials in China
    (Beijing Northland Biotech)

  • 04

    Changed name to Helixmith.

2018
  • 08

    Kim Sun-young, became a sole representative as CEO.​

  • 07

    Established Genopis Inc., contract manufacturing organization.​

  • 05

    VM2020 designated as a Regenerative Medicine Advanced Theraphy
    (RMAT) by the FDA for treatment of DPN

2017
  • 04

    VM507, Selected as Government Support Research Projects
    VM202-PAD(Peripheral Artery Disease), approved in phase 3 clinical trials in China.​​

2016
  • 09

    VM202-ALS (Amyotrophic Lateral Sclerosis), Phase 1/2 clinical trials in US​.

  • 08

    VM202-CAD(Coronary Artery Disease) Launches Phase 2 in Korea.​

  • 05

    VM202-ALS(Amyotrophic Lateral Sclerosis), U.S. FDA fast track designation​.

2015
  • 12

    Technology transfer contract signed by U.S. company Bluebird Bio for CAR-T treatment.​

  • 08

    VM202-PAD(Peripheral Artery Disease), initiated phase 3 clinical trials in U.S.

  • 04

    VM202-DPN(Diabetic Peripheral Neuropathy), initiated phase 3-1 clinical trials in U.S.(VMDN-003)

2014
  • 05

    VM202-CAD(Coronary Artery Disease) for ischemic heart disease,
    signed a development catheter supply contract.
    VM202-ALS(Amyotrophic Lateral Sclerosis), Selected as the Ministry of
    Health and Welfare's Advanced Medical Technology Development Project.​

  • 02

    VM202-ALS(Amyotrophic Lateral Sclerosis), Received orphan drug desingation from FDA
    Gongshinbogam®(Health functional food for memory improvement) to be released.​

2013
  • 12

    VM202-ALS(Amyotrophic Lateral Sclerosis) Joint development contract with Reyon Pharmaceuticals Co.Ltd.​

  • 10

    VM202-ALS(Amyotrophic Lateral Sclerosis), Initiated Phase 1/2 clinical trial in U.S.​

  • 01

    Muppin® (Health functional foods to improve articulation and cartilage health) released​.

2012
  • 12

    LAYLA TAB™(Anthritis Treatment) relaeased in Korean market​
    VM202-DPN(Diabetic Neuropathy Treatment), Healthcare R&D Project Selection​.

  • 07

    Transferred technology for chronic hepatitis type B vaccines to Reyon Pharmaceutical Co., Ltd. ​

  • 03

    VM202-DPN(Diabetic Neuropathy Treatment), initiated phase 2 clinical trials in Korea​
    VM501(Thrombocytopenia Treatment) initiated Phase 3 clinical trials in China​
    PG201(Osteoarthritis) Korea's 7th Natural Products New Drug License​.

2011
  • 12

    VM505 (antibody anticancer treatment) Joint development agreement with Pharmaceuticals Co., Ltd.​

  • 11

    VM202-DPN(Diabetic Neuropathy Treatment) Initiated Phase 2 clinical trial (VMDN-002) in the U.S.

  • 09

    PG201(Osteoarthritis), applied for patent authorization in Korea​
    VM202-PAD(Peripheral Artery Disease) Initiates Phase II of Clinical Practice.

  • 02

    VM206RY initiated clinical trial phase 1 in Korea

  • 01

    2011 Alex i™ (health functional food for relieving immune hypersensitivity) released in Korean market

2010
  • 10

    VM202-PAD(Peripheral Artery Disease)initiated clinical trials phase 2 in Korea​.

  • 07

    Kim Yong-soo, became a sole representative as CEO.​

2009
  • 11

    Alex® (health functional food for relieving immune hypersensitivity) and Ato Latte® (moisturizer) released
    ​Heliccer Acquisition and Acquisition, Health Functional Food and New Natural
    Products Pipeline secured.​

  • 07

    VM202-PAD (Ischemic retarded disease treatment), initiated phase 2
    clinical trials in U.S.
    ​ Kim Sun-young and Kim Yong-soo became Individual Representatives.​

  • 03

    VM202-CAD (Healthy Heart Disease Therapy), initiated clinical trial
    phase 1/2 in U.S.​
    VM202-DPN (Diabetic Neuropathy Therapy),initiated clinical trial
    phase 1/2 in U.S.​
    PG102(Improvement of immune hypersensitivity), obtained individual
    certification from the Ministry of Food and Drug Safety

2008
  • 10

    Selected as BioStar Project by Ministry of Knowledge Economy

  • 07

    Signed an MOU with Cobra Biologics, UK.

  • 06

    VM202-PAD(Peripheral Artery Disease) initiated clinical trial phase 1 in China.​

  • 01

    VM206(anticancer gene therapy vaccine), technology transfer to Reyon Pharmaceutical Co., Ltd.​

2007
  • 11

    Signed a contract with Korea Institute of Biotechnology to introduce targeted cancer treatment
    technology​.

  • 10

    Signed a contract with Yonsei University to introduce selective tumor killing adenovirus technology​.

  • 01

    VM106(Chronic Granulomatous Disease Therapy) initiated clinical trials phase I/II in Korea.

2006
  • 11

    VM202-CAD(Coronary Artery Disease) initiated clinical trial phase 1 in U.S.​

  • 10

    VM202RY(Ischemic Coronary Artery Disease) initiated clinical trial phase 1 in Korea.

  • 09

    Exclusive Sales Agreement with Takara Bio, Japan​.

  • 01

    VM106(Chronic Granulomatous Disease Therapy), joint development of Yuhan Corp.
    ​ Forming a Strategic Solidarity Agreement with Japan's Takara Bio Company​

2005
  • 12

    Listed on the KOSDAQ

  • 06

    VM501 (Thrombocytopenia Treatment), technology transfer to GC Pharma.​

  • 05

    Technology Transfer of Retroviral Vector to Takara Bio, Japan​.

2004
  • 12

    Signed a Joint Research Agreement with Yuhan Corporation​.

  • 07

    Signed Cross licensing agreement with Beijing Northland, China​.

  • 01

    VMDA-3601(Icshemic foot disease treatment), initiated clinical trials phase 2 in Korea​
    VM202RY (Heptic coronary artery disease treatment),
    technology transfer to Reyon Pharmaceutical Co., Ltd.​

2003
  • 02

    Initiated consignment manufacturing of recombinant retrovirus​

2001
  • 02

    VMDA-3601(Icshemic foot disease treatment), initiated clinical trial phase 1 in Korea​.

2000
  • 04

    Investment of $6 Million from Takara Shuzo, Japan​.

1999
  • 10

    Establishment of joint venture VioTech Ltd with Oxford Biomedica, UK​

  • 09

    Company renamed to Viromed​.

1998
  • 09

    Seoul Regional Small and Medium Business
    Administration's certification of venture businesses​.

  • 05

    Export of Retroviral Vector to Takara Shuzo, Japan​

1997
  • 03

    Technology Export to Oxford Biomedica, UK​

  • 01

    Enactment of Green Cross Service Research Agreement​

1996
  • 11.21

    Established as Byromedica Pacific Co., Ltd.​